Emergent BioSolutions (NYSE:EBS) Coverage Initiated at HC Wainwright

HC Wainwright started coverage on shares of Emergent BioSolutions (NYSE:EBS) in a research note published on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $15.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. Benchmark raised their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Rodman & Renshaw restated a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th. Finally, StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Saturday.

Emergent BioSolutions Stock Up 11.9 %

EBS opened at $9.25 on Monday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The business’s fifty day simple moving average is $9.19 and its 200 day simple moving average is $8.91. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $15.10. The stock has a market cap of $501.20 million, a PE ratio of -2.26 and a beta of 1.59.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EBS. Federated Hermes Inc. boosted its position in Emergent BioSolutions by 1,314.0% during the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after buying an additional 253,960 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Emergent BioSolutions during the third quarter worth about $1,547,000. Headlands Technologies LLC bought a new stake in shares of Emergent BioSolutions in the second quarter worth about $969,000. Oak Hill Advisors LP purchased a new position in Emergent BioSolutions during the 3rd quarter valued at about $9,296,000. Finally, Assenagon Asset Management S.A. raised its position in Emergent BioSolutions by 74.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after purchasing an additional 316,700 shares during the last quarter. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.